Barclays PLC Mirum Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $353 Billion
- Q1 2025
A detailed history of Barclays PLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 81,304 shares of MIRM stock, worth $3.68 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
81,304
Previous 251,964
67.73%
Holding current value
$3.68 Million
Previous $10.4 Million
64.84%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding MIRM
# of Institutions
224Shares Held
55.3MCall Options Held
27.4KPut Options Held
105K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$308 Million19.27% of portfolio
-
Janus Henderson Group PLC London, X04.77MShares$216 Million0.12% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$147 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$127 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$115 Million0.0% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.66B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...